NASH is a newly launched Dutch biotech co-founded and led by the former CEO of Dezima. The company is developing a therapy targeting non-alcoholic steatohepatitis (NASH). It is preparing to enter Phase IIB clinical development. NASH launched with €25 million in startup capital. That funding comes from prominent European investors named in the report. No operating metrics or revenue figures were disclosed in the article.

Total raised

$29M

Funding rounds

1

Latest round

Equity

Latest activity

Dec 2017